Janus Henderson Investors US’s Stemline Therapeutics, Inc. STML Stock Holding History

Janus Henderson Investors US’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-495,384	Closed	-$7.27M	–	1140
2014 Q2	$7.27M	Buy	495,384 +66,306	+15%	+$1.02M	0.01%	735
2014 Q1	$8.74M	Buy	429,078 +49,337	+13%	+$1.2M	0.01%	689
2013 Q4	$7.44M	Sell	379,741 -16,878	-4%	-$450K	0.01%	715
2013 Q3	$18M	Buy	396,619 +99,926	+34%	+$3.26M	0.02%	549
2013 Q2	$7.07M	Buy	+296,693	New	+$4.73M	0.01%	664

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Janus Henderson Investors US's STML Position: Q3 2014 in Review

Janus Henderson Investors US sold out of Stemline Therapeutics, Inc. (STML) in Q3 2014, closing a stake of 495,384 shares — an estimated $7.27M sold.

Janus Henderson Investors US first reported a position in STML in Q2 2013 and held it in 5 quarters. The position peaked at $18M in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q3 2014.

Janus Henderson Investors US reported no remaining Stemline Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
Janus Henderson Investors US sold 495,384 Stemline Therapeutics, Inc. shares in Q3 2014, an estimated $7.27M.
Janus Henderson Investors US first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
Janus Henderson Investors US's Stemline Therapeutics, Inc. position peaked at $18M in Q3 2013.
61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2014.

Based on Janus Henderson Investors US's 13F filing for Q3 2014, filed 14 Nov 2014.